BeOne Medicines (BEIGF) Cash & Equivalents Growth (5y) (2020 - 2026)
Powered by 
Analysis
BeOne Medicines (BEIGF) Cash & Equivalents Growth (5y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.47 Bn | 624.71 Bn | 17.26 Bn |
| 2 | AbbVie | 439.99 Bn | 433.42 Bn | 12.70 Bn |
| 3 | Merck | 365.45 Bn | 358.31 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.57 Bn | 258.88 Bn | 11.24 Bn |
| 5 | Pfizer | 159.03 Bn | 147.33 Bn | 10.94 Bn |
| 6 | Sanofi | 52.43 Bn | 45.05 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.23 Bn | 44.23 Bn | - |
| 8 | Incyte | 25.32 Bn | 20.79 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.44 Bn | 18.77 Bn | 683.80 Mn |
| 10 | BeOne Medicines | 2.48 Bn | -2.62 Bn | 1.53 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 23.47% |
| Mar 31, 2026 | 20.30% |
| Dec 31, 2025 | 26.90% |
| Sep 30, 2025 | 22.48% |
| Jun 30, 2025 | 15.43% |
| Mar 31, 2025 | 5.16% |
| Dec 31, 2024 | 33.57% |
| Sep 30, 2024 | 25.82% |
| Jun 30, 2024 | 23.05% |
| Mar 31, 2024 | 29.58% |
| Dec 31, 2023 | 34.79% |
| Sep 30, 2023 | 36.66% |
| Jun 30, 2023 | 50.72% |
| Mar 31, 2023 | 48.46% |
| Dec 31, 2022 | 74.44% |
| Sep 30, 2022 | 82.29% |
| Jun 30, 2022 | 76.97% |
| Mar 31, 2022 | 113.61% |
| Dec 31, 2021 | 118.67% |
| Sep 30, 2021 | 74.49% |